<DOC>
	<DOCNO>NCT00806182</DOCNO>
	<brief_summary>The purpose study determine cytokine , inflammatory mediator , increase spinal fluid blood , correlate disease activity , could serve biomarkers therapeutic target child opsoclonus-myoclonus syndrome ( OMS ) , autoimmune complication tumor neuroblastoma .</brief_summary>
	<brief_title>Study Cytokines Children With Opsoclonus-Myoclonus Syndrome</brief_title>
	<detailed_description>In translational research , immunological mechanism underlie assault immune system brain paraneoplastic opsoclonus-myoclonus syndrome ( OMS ) evaluation . To test principal hypothesis imbalance pro-inflammatory ( Th1 ) anti-inflammatory ( Th2 ) cytokines OMS , comprehensive cytokine panel measure enzyme-linked immunosorbent assay ( ELISA ) multiplexed fluorescent bead-based immunoassay detection ( LUMINEX 100 Lab MAP system ) blood cerebrospinal fluid ( CSF ) 400 child . To test second hypothesis cytokine could serve biomarkers disease activity OMS , cytokine concentration correlate clinical variable , disease severity , OMS duration , prior relapse , remission , well immunological variable , lymphocyte subset analysis . The cytokine 'biomarker profile ' could aid decision make early intervention identify child high risk relapse poor outcome allow target implicated inflammatory cytokine cytokine therapy . To test third hypothesis lack response immunotherapy due part failure increase expression anti-inflammatory Th2 cytokine , make pair pre/post comparison impact immunotherapy give course clinical care [ steroid , adrenocorticotropin ( ACTH ) , intravenous immunoglobulin ( IVIg ) , rituximab , chemotherapy , drug , combination ] cytokine clinical profile . This research could lead application commercially-available cytokine cytokine blocker development new one OMS .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Myoclonus</mesh_term>
	<mesh_term>Ocular Motility Disorders</mesh_term>
	<mesh_term>Opsoclonus-Myoclonus Syndrome</mesh_term>
	<criteria>Clinical diagnosis OMS Equivocal diagnosis Contraindications lumbar puncture Treatment agent outside scope study</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>paraneoplastic</keyword>
	<keyword>neuroblastoma</keyword>
	<keyword>Kinsbourne syndrome</keyword>
	<keyword>autoimmune disease</keyword>
	<keyword>immunotherapy</keyword>
	<keyword>ataxia</keyword>
</DOC>